Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
P46 - Novel Therapeutics and Targeted Therapies - Case Report
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 7
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P46.01 - Progression After Targeted-therapy – An EGFR Case Report
00:00 - 00:00 | Presenter: Francisco Neri
- Abstract
Loading... -
+
P46.02 - Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib.
00:00 - 00:00 | Presenter: Edyta Maria Urbanska
- Abstract
Loading... -
+
P46.03 - Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC
00:00 - 00:00 | Presenter: Jens Benn Sørensen
- Abstract
Loading... -
+
P46.04 - Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants
00:00 - 00:00 | Author(s): Yoko Nakanishi
- Abstract
Loading... -
+
P46.05 - Durable Response to Double Dose Osimertinib 160mg in EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases
00:00 - 00:00 | Presenter: Myungwoo Nam
- Abstract
Loading... -
+
P46.06 - Response of an Advanced Lung Cancer Mass to Targeted Therapy
00:00 - 00:00 | Presenter: Paulo Alfredo Casanova Schulze
- Abstract
Loading... -
+
P46.07 - Afatinib-Related Pneumonitis in Metastatic EGFR-Positive NSCLC
00:00 - 00:00 | Presenter: Sita Andarini
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P47.01 - SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress)
00:00 - 00:00 | Presenter: Martin Reck
- Abstract
Loading... -
+
P47.02 - EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer
00:00 - 00:00 | Author(s): Kei Muro
- Abstract
Loading... -
+
P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading... -
+
P47.04 - TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC
00:00 - 00:00 | Presenter: Benjamin Levy
- Abstract
Loading... -
+
P47.05 - A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)
00:00 - 00:00 | Presenter: Melissa L Johnson
- Abstract
Loading... -
+
P47.06 - TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC
00:00 - 00:00 | Presenter: Hossein Borghaei
- Abstract
Loading... -
+
P47.07 - KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading... -
+
P47.08 - A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading... -
+
P47.09 - Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
00:00 - 00:00 | Presenter: Christophe Dooms
- Abstract
Loading... -
+
P47.10 - Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study
00:00 - 00:00 | Presenter: Waleed Kian
- Abstract
Loading... -
+
P47.11 - COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
00:00 - 00:00 | Presenter: Lecia V. Sequist
- Abstract
Loading... -
+
P47.12 - ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression
00:00 - 00:00 | Presenter: Malinda Itchins
- Abstract
Loading... -
+
P47.13 - First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading... -
+
P47.14 - Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC
00:00 - 00:00 | Presenter: Reiko Matsuzawa
- Abstract
Loading... -
+
P47.15 - A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results
00:00 - 00:00 | Presenter: Matthew Lara
- Abstract
Loading... -
+
P47.16 - Preliminary Efficacy and Safety Results About a Phase II Trial of Afatinib and Bevacizumab in Untreated NSCLC Harboring EGFR Sensitive Mutations
00:00 - 00:00 | Presenter: Yu Feng
- Abstract
Loading... -
+
P47.17 - Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)
00:00 - 00:00 | Presenter: Pierre-Jean Souquet
- Abstract
Loading... -
+
P47.18 - Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial)
00:00 - 00:00 | Presenter: Nan Bi
- Abstract
Loading...
-
+
P48 - Novel Therapeutics and Targeted Therapies - EGFR
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 17
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P48.01 - Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P48.02 - Real-World Data of Dacomitinib in EGFR TKI-Naïve Patients With Advanced Epidermal Growth Factor Receptor-positive Non-small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jinyao Zhang
- Abstract
Loading... -
+
P48.03 - Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients
00:00 - 00:00 | Presenter: Moushumi Suryavanshi
- Abstract
Loading... -
+
P48.04 - EGFR Germline Mutations in Chinese Lung Cancer Patients: A Single Institutional, Retrospective Study
00:00 - 00:00 | Presenter: Chengzhi Zhou
- Abstract
Loading... -
+
P48.05 - Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
00:00 - 00:00 | Presenter: Miguel Garcia
- Abstract
Loading... -
+
P48.06 - A Network Meta-Analysis (MA) of First-Line Lung Cancer Treatment With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
00:00 - 00:00 | Presenter: Yvonne Ang
- Abstract
Loading... -
+
P48.07 - Real-World Impact of Upfront Osimertinib in Reducing Health Resource Utilization by Preventing Brain Metastases
00:00 - 00:00 | Presenter: Francesca Simionato
- Abstract
Loading... -
+
P48.08 - The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
P48.09 - Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
00:00 - 00:00 | Presenter: Oscar Arrieta
- Abstract
Loading... -
+
P48.10 - Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
P48.11 - ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC Patients
00:00 - 00:00 | Presenter: Weineng Feng
- Abstract
Loading... -
+
P48.12 - Concurrent Chemotherapy and First-Generation EGFR-TKI as First-Line Treatment in Advanced Lung Adenocarcinoma Harboring EGFR Mutation
00:00 - 00:00 | Presenter: Ziyi Xu
- Abstract
Loading... -
+
P48.13 - Clinical Factors Associated With Treatment Outcomes in EGFR Mutant Non-Small Cell Lung Cancer Patients. Real Life Experience in Argentina
00:00 - 00:00 | Presenter: luis Roberto basbus
- Abstract
Loading... -
+
P48.14 - Metastatic NSCLC -Re-Challenging With Fist Generation TKI After a Drug Free Holiday After Resistance to 3rd Generation TKI
00:00 - 00:00 | Presenter: Suryakanta Acharya
- Abstract
Loading... -
+
P48.15 - EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way?
00:00 - 00:00 | Presenter: Marta Soares
- Abstract
Loading... -
+
P48.16 - The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis
00:00 - 00:00 | Presenter: Yinchen Shen
- Abstract
Loading... -
+
P48.17 - Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
00:00 - 00:00 | Presenter: Jorge Nieva
- Abstract
Loading...
-
+
P49 - Novel Therapeutics and Targeted Therapies - EGFR Major
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 1
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P49.01 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC
00:00 - 00:00 | Presenter: Song Dong
- Abstract
Loading...
-
+
P50 - Novel Therapeutics and Targeted Therapies - EGFR Minor
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P50.01 - RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants
00:00 - 00:00 | Presenter: Kazumi Nishino
- Abstract
Loading... -
+
P50.03 - A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
00:00 - 00:00 | Presenter: Satoru Miura
- Abstract
Loading... -
+
P50.04 - Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Misako Nagasaka
- Abstract
Loading... -
+
P50.05 - Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study
00:00 - 00:00 | Presenter: Madhusmita Behera
- Abstract
Loading... -
+
P50.06 - First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
00:00 - 00:00 | Author(s): Arsela Prelaj
- Abstract
Loading... -
+
P50.07 - Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations in Chinese Population
00:00 - 00:00 | Presenter: Teng Li
- Abstract
Loading... -
+
P50.08 - Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India
00:00 - 00:00 | Presenter: Vivek Joseph Varughese
- Abstract
Loading... -
+
P50.09 - Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice
00:00 - 00:00 | Presenter: Yejeong Han
- Abstract
Loading...
-
+
P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 7
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P51.01 - Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
00:00 - 00:00 | Presenter: Chong Kin Liam
- Abstract
Loading... -
+
P51.02 - Stacking on the Targets: Secondary Resistant, Potential Targetable Genetic Alterations in Patients With Epidermal Growth Factor Receptor NSCLC
00:00 - 00:00 | Presenter: Nagashree Seetharamu
- Abstract
Loading... -
+
P51.03 - Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial
00:00 - 00:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
P51.04 - Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR- Mutated Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Hyesook Kim
- Abstract
Loading... -
+
P51.05 - Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study
00:00 - 00:00 | Presenter: Sanjay Popat
- Abstract
Loading... -
+
P51.06 - Outcomes of First-Line TKI Treated Advanced NSCLC with Distinct Types of EGFR Mutations: Brain Metastasis and de Novo T790M
00:00 - 00:00 | Presenter: Ya Zeng
- Abstract
Loading... -
+
P51.07 - Small Cell Transformation of Non Small Cell Lung Carcinoma: Tissue Biopsy Is Here to Stay!
00:00 - 00:00 | Presenter: Mansi Sharma
- Abstract
Loading...
-
+
P52 - Novel Therapeutics and Targeted Therapies - KRAS
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 5
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P52.01 - Understanding Treatment Preferences of Patients With KRAS p.G12C[LC1] [MK2] – Mutated Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Kelley Myers
- Abstract
Loading... -
+
P52.02 - High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Hui-Bo Feng
- Abstract
Loading... -
+
P52.03 - Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
00:00 - 00:00 | Presenter: Suresh Ramalingam
- Abstract
Loading... -
+
P52.04 - Histone Deacetylase 6 Inhibition Reveals Metabolic Vulnerabilities in KRAS Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Catriona M Dowling
- Abstract
Loading... -
+
P52.05 - Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
00:00 - 00:00 | Author(s): Silvia Coma
- Abstract
Loading...
-
+
P53 - Novel Therapeutics and Targeted Therapies - Others
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P53.01 - Clinical Application of NGS Technology. Therapeutic Possibilities and Future Perspectives
00:00 - 00:00 | Presenter: Silvia Sequero-Lopez
- Abstract
Loading... -
+
P53.02 - Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
00:00 - 00:00 | Presenter: Alexander Drilon
- Abstract
Loading... -
+
P53.03 - The Characteristics of FGFR Genetic Aberrations in Chinese Lung Cancer Patients
00:00 - 00:00 | Presenter: Xiuqin Zhang
- Abstract
Loading... -
+
P53.04 - Local Therapies vs. Specific TKIs as the Initial Treatment for Oligo-Recurrent Lung Adenocarcinoma With Driver Mutations
00:00 - 00:00 | Presenter: Yosuke Matsuura
- Abstract
Loading... -
+
P53.05 - Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC
00:00 - 00:00 | Presenter: Emily K Kleczko
- Abstract
Loading... -
+
P53.06 - A Multi-Phase Quality Initiative to Improve Processes of Care for Non-small Cell Lung Cancer (NSCLC) in US Community Cancer Centers
00:00 - 00:00 | Presenter: Matthew Smeltzer
- Abstract
Loading... -
+
P53.07 - Clinical and Genomic Insights Into of Chinese Lung Cancer Patients with HER2 Amplification
00:00 - 00:00 | Presenter: Chengzhi Zhou
- Abstract
Loading... -
+
P53.08 - Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration
00:00 - 00:00 | Presenter: William A Stokes
- Abstract
Loading...
-
+
P54 - Palliative and Supportive Care
- Type: Posters
- Track: Palliative and Supportive Care
- Presentations: 6
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P54.01 - Analysis of the Support Needs of Lung Cancer Patients
00:00 - 00:00 | Author(s): Paris Kosmidis
- Abstract
Loading... -
+
P54.02 - Palliative Treatment of Tumor Stenoses of the Trachea and Bronchi
00:00 - 00:00 | Presenter: Vladyslav Severgin
- Abstract
Loading... -
+
P54.03 - Bilateral Indwelling Pleural Catheters
00:00 - 00:00 | Presenter: Avinash Aujayeb
- Abstract
Loading... -
+
P54.04 - Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices
00:00 - 00:00 | Presenter: Maria Torrente
- Abstract
Loading... -
+
P54.05 - Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience
00:00 - 00:00 | Presenter: Süreyya Sarıhan
- Abstract
Loading... -
+
P54.06 - The FITNESS Study: Geriatric Assessment, Treatment Toxicity, and Biospecimen Collection Among Older Adults With Lung Cancer
00:00 - 00:00 | Presenter: Madison Grogan
- Abstract
Loading...
-
+
P55 - Patient Advocacy
- Type: Posters
- Track: Patient Advocacy
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P55.01 - Standard of Care Disparity in a Global Cancer Support Group: Examining an Advocate Survey to Inspire Change.
00:00 - 00:00 | Presenter: Jamie Gibbard
- Abstract
Loading... -
+
P55.02 - Robotic Surgery in Canada: Are Patients Willing to Pay Out-of-Pocket?
00:00 - 00:00 | Presenter: Yogita S. Patel
- Abstract
Loading... -
+
P55.03 - Results of The First Survey Using EORTC QLQ INFO25 on Information Acquisition and Satisfaction of Lung Cancer Patients in Japan
00:00 - 00:00 | Presenter: Takayuki Takahama
- Abstract
Loading...
first
prev
